Biotechnology News and Research

RSS

Pacira reports net loss of $7.0 million for quarter ended December 31, 2010

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the fourth quarter and full-year ended December 31, 2010, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL and established 2011 financial guidance.

31 Mar 2011

Glasgow Professor discusses about new approach for CML treatment at UK conference

Speaking at the UK National Stem Cell Network conference in York later today, Professor Tessa Holyoake from the University of Glasgow will discuss a brand new approach to treating chronic myeloid leukaemia in which a small number of cancer cells persist despite effective therapy thus preventing cure.

31 Mar 2011

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC).

31 Mar 2011

20-year data shows bariatric surgery to reduce risk of heart attack and stroke in diabetics

In the longest study of its kind, bariatric surgery has been shown to reduce the risk of heart attack and stroke in patients with diabetes. These results and other groundbreaking research were presented at the 2nd World Congress on Interventional Therapies for Type 2 Diabetes, hosted by NewYork-Presbyterian Hospital and Weill Cornell Medical College.

31 Mar 2011

3D experiments reveal MSCs have potential to produce different cell types

A type of adult stem cell is now proving itself more versatile for research and therapies thanks to revolutionary 3D experiments. These cells have already shown great promise for repairing damaged bone and cartilage but until now have been fairly limited in the types of cells they can form in the laboratory.

31 Mar 2011

KSB, SuperNova sign agreement to develop and commercialize Neopterin

SuperNova Diagnostics, a privately-held global diagnostics company for human and non-human health applications, announced today that it has signed an agreement with Shenzhen Kang Sheng Bao Bio-Technology, a biotechnology diagnostics company specializing in research, manufacture and distribution of in-vitro diagnostic kits and research reagents in China and affiliated markets for the research, development, manufacture and commercialisation of diagnostic products and services for the measurement of Neopterin, its metabolites and derivatives utilising the SuperNova technology platform of AmpCrystal.

31 Mar 2011

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

Amgen, Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer.

30 Mar 2011

DSP, Intercept enter license agreement for OCA

Dainippon Sumitomo Pharma Co, Ltd. and Intercept Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid.

30 Mar 2011

FDA grants orphan drug status to America Stem Cell's ASC-101

America Stem Cell, Inc. announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to ASC-101 to improve homing to bone marrow in patients receiving hematopoietic stem cell transplantation.

30 Mar 2011

Los Alamos National Lab, Biomagnetics to develop and commercialize IOBS system

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced further details in next steps to be taken toward full commercialization of the Company's flagship Integrated Optical Biosensor diagnostic system.

30 Mar 2011

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

Silence Therapeutics plc a leading global RNA interference therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, have been accepted for poster presentation at the 2011 American Society of Clinical Oncology Annual Meeting.

30 Mar 2011

Pathfinder cell-based therapy reverses diabetes in mouse model

Pathfinder, LLC, a private biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced publication of promising preclinical data demonstrating that the Company's unique cell-based therapy is able to completely reverse diabetes in a mouse model.

30 Mar 2011

Stanford pediatrics receives Genzyme/ACMG award for biochemical genetic research

Anna-Kaisa Niemi, MD, Ph.D., a resident in Medical Genetics in the Department of Pediatrics, Division of Medical Genetics at the Stanford University Medical Center, in Stanford Calif., was honored as the 2011-2012 recipient of the Genzyme/American College of Medical Genetics Foundation Clinical Genetics Fellowship in Biochemical Genetics at the ACMG 2011 Annual Clinical Genetics Meeting in Vancouver, BC, Canada.

30 Mar 2011

Mary Ann Liebert to launch new 'Shingles and PHN' open access journal

Shingles and PHN, a new, bimonthly open access peer-reviewed journal, will be launched in fall 2011 by Mary Ann Liebert, Inc., publishers.

30 Mar 2011

Labcyte launches 1536-well tissue-culture treated microplate for cell-based screening

Labcyte Inc. today launched a new 1536-well tissue-culture treated microplate for cell-based screening and discovery applications. By enabling cell culture directly in a high-density microplate, this new product expands cell-based assay miniaturization capabilities, such as direct PCR from cell cultures.

30 Mar 2011

Transgenomic discovers novel BLOCker-Sequencing technology

Transgenomic, Inc. today announced that it has discovered a novel sequencing technology, which the company has termed BLOCker-Sequencing, which enhances the limit of detection of standard Sanger Sequencing, enriches for direct sequencing of mutated DNA over wild-type and can be run on standard Sanger Sequencing equipment.

30 Mar 2011

Concert initiates CTP-499 Phase 1 study in patients with diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced it has made significant progress advancing CTP-499, its novel anti-inflammatory, anti-oxidant, and anti-fibrotic agent for diabetic nephropathy and other forms of chronic kidney disease, into clinical development.

29 Mar 2011

Cephalon intends to make takeover bid for ChemGenex

Cephalon, Inc. and ChemGenex Pharmaceuticals Limited today jointly announced that Cephalon's wholly-owned subsidiary, Cephalon CXS Holdings Pty Ltd, intends to make a takeover bid for ChemGenex.

29 Mar 2011

PPD introduces new mobile application for clinical trial searches

PPD, Inc. today announced it has launched its new Clinical Trials Mobile application for use on Apple iPad and Apple iPhone devices to help potential clinical research participants and investigators find clinical trials across a wide range of therapeutic areas.

29 Mar 2011